Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure

• Status: Active, not recruiting
• Trial end date: 2020-10-31
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared with placebo, on heart failure disease-specific biomarkers, symptoms, health status, and quality of life in patients with chronic heart failure with reduced systolic function.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Saint Luke's Health System
• Treatments: Dapagliflozin

Criteria

Inclusion Criteria:

1. Established diagnosis of NYHA Class II or Class III heart failure (LVEF≤40% due to either ischemic or non-ischemic etiology) with reduced systolic function for at least 16 weeks prior to enrollment

2. No change in diuretic management for at least 1 week prior to enrollment

3. BNP ≥100 pg/mL and/or NTproBNP ≥ 400 pg/mL at enrollment

Exclusion Criteria:

1. History of type 1 diabetes

2. Estimated glomerular filtration rate (eGFR) < 30 at enrollment

3. Hospitalization for heart failure within the 30 days prior to enrollment

4. Admission for an acute coronary syndrome (ST-elevation MI, non-ST-elevation MI, or unstable angina), percutaneous coronary intervention, or cardiac surgery within the 30 days prior to enrollment

5. Admission for cardiac resynchronization therapy (CRT) within 90 days prior to the screening visit

6. Planned cardiovascular revascularization (percutaneous intervention or surgical) or major cardiac surgery (coronary artery bypass grafting, valve replacement, ventricular assist device, cardiac transplantation, or any other surgery requiring thoracotomy) within the 90 days after enrollment

7. Patients who are volume depleted based upon physical examination at the time of screening or randomization